MOTS-c (Mitochondrial ORF of the 12S rRNA type-c) occupies a genuinely unique position in peptide biology. While most peptides are encoded in nuclear DNA, MOTS-c is encoded directly in the mitochondrial genome — specifically within the 12S ribosomal RNA gene. This makes it one of a small family of mitochondrial-derived peptides (MDPs) that act as retrograde signals from the mitochondria to the nucleus, communicating the metabolic state of the cell and coordinating whole-body responses to stress and energy demand.

Discovered in 2015 by the Pinchas Cohen lab at USC, MOTS-c quickly attracted attention for two reasons. First, it potently activates AMPK — the master cellular energy sensor that also underlies the metabolic benefits of exercise and caloric restriction. Second, its circulating levels decline measurably with age and are significantly lower in people with metabolic syndrome, type 2 diabetes, and obesity. The correlation is compelling: MOTS-c appears to be one of the molecular links between mitochondrial health and systemic metabolic aging.

What makes MOTS-c particularly interesting from a longevity perspective is the exercise-mimetic effect. MOTS-c is acutely elevated by physical exercise, and much of what exercise does for insulin sensitivity, glucose uptake, and fat oxidation appears to be mediated, at least in part, through MOTS-c signaling. Injectable MOTS-c essentially delivers that mitochondrial signal directly — without the exercise stimulus required to generate it.

• 1 AMPK activation — the exercise-mimetic core mechanism. MOTS-c directly activates AMPK (AMP-activated protein kinase), the master sensor of cellular energy status. AMPK activation increases glucose uptake in skeletal muscle, promotes fatty acid oxidation, inhibits fat synthesis, and stimulates mitochondrial biogenesis. This is the same pathway activated by exercise, caloric restriction, and the drug metformin — making MOTS-c one of the few peptides that genuinely mimics the metabolic benefits of physical activity at the cellular level.
• 2 Insulin sensitivity and glucose homeostasis. MOTS-c improves insulin sensitivity in skeletal muscle and liver tissue, the two primary sites of glucose disposal. In high-fat diet mouse models, MOTS-c administration prevented the development of insulin resistance and reduced fasting glucose. In humans, lower circulating MOTS-c is consistently observed in type 2 diabetes and metabolic syndrome, suggesting it plays a protective role in maintaining insulin signaling that is lost with age and metabolic stress.
• 3 Mitochondrial stress response and oxidative resilience. MOTS-c functions as a retrograde stress signal from the mitochondria to the nucleus, activating transcriptional programs that increase the cell's capacity to handle metabolic stress and oxidative damage. This includes upregulation of antioxidant defenses and improvement in mitochondrial membrane integrity. The result is a cell that handles energy demand more efficiently and recovers more quickly from metabolic insults — relevant to both exercise performance and aging.
• 4 Anti-inflammatory signaling and lifespan extension. MOTS-c suppresses NF-κB-driven inflammation — the same pathway implicated in inflammaging. In aged mouse models, regular MOTS-c administration extended median lifespan by approximately 18%, improved physical performance, and reduced markers of systemic inflammation. The combination of anti-inflammatory and metabolic effects appears to be synergistic, positioning MOTS-c as both a healthspan and potential lifespan intervention.